Investor Relations News
-
Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the reduction of scarring and acceleration of healing, today received notification (subsequent to the release of the... read more
-
TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Renovo Group plc 2.... read more
-
TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Renovo Group plc 2.... read more
-
12 MONTH ANALYSIS OF JUVISTA® CLINICAL TRIALS RN1001-0050 & RN1001-0036 Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the reduction of scarri... read more
-
TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Renovo Group plc 2.... read more